CY2014015I1 - Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου - Google Patents

Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου

Info

Publication number
CY2014015I1
CY2014015I1 CY2014015C CY2014015C CY2014015I1 CY 2014015 I1 CY2014015 I1 CY 2014015I1 CY 2014015 C CY2014015 C CY 2014015C CY 2014015 C CY2014015 C CY 2014015C CY 2014015 I1 CY2014015 I1 CY 2014015I1
Authority
CY
Cyprus
Prior art keywords
glycopyrrolic
methods
dry powder
powder compositions
preparing dry
Prior art date
Application number
CY2014015C
Other languages
English (en)
Other versions
CY2014015I2 (el
Original Assignee
Vectura Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32408337&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY2014015(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Vectura Limited filed Critical Vectura Limited
Publication of CY2014015I2 publication Critical patent/CY2014015I2/el
Publication of CY2014015I1 publication Critical patent/CY2014015I1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CY2014015C 2004-04-30 2014-03-19 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου CY2014015I1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0409703.6A GB0409703D0 (en) 2004-04-30 2004-04-30 Pharmaceutical compositions
PCT/EP2005/051980 WO2005105043A2 (en) 2004-04-30 2005-04-29 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
CY2014015I2 CY2014015I2 (el) 2015-12-09
CY2014015I1 true CY2014015I1 (el) 2015-12-09

Family

ID=32408337

Family Applications (6)

Application Number Title Priority Date Filing Date
CY20121100722T CY1113069T1 (el) 2004-04-30 2012-08-13 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY2013012C CY2013012I1 (el) 2004-04-30 2013-03-29 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY2014015C CY2014015I1 (el) 2004-04-30 2014-03-19 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY20151100754T CY1116655T1 (el) 2004-04-30 2015-08-27 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015059C CY2015059I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015060C CY2015060I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20121100722T CY1113069T1 (el) 2004-04-30 2012-08-13 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
CY2013012C CY2013012I1 (el) 2004-04-30 2013-03-29 Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου

Family Applications After (3)

Application Number Title Priority Date Filing Date
CY20151100754T CY1116655T1 (el) 2004-04-30 2015-08-27 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015059C CY2015059I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου
CY2015060C CY2015060I1 (el) 2004-04-30 2015-12-23 Συνθεσεις ξηρης σκονης γλυκοπυρρολικου και στεατικου μαγνησιου

Country Status (27)

Country Link
US (1) US20080063719A1 (el)
EP (3) EP1755555B1 (el)
JP (2) JP5000483B2 (el)
KR (1) KR101287919B1 (el)
CN (3) CN1964700A (el)
AU (2) AU2005237266B2 (el)
BR (1) BRPI0510500B8 (el)
CA (1) CA2563760C (el)
CY (6) CY1113069T1 (el)
DK (2) DK2422766T3 (el)
ES (2) ES2388289T3 (el)
GB (1) GB0409703D0 (el)
HK (2) HK1095282A1 (el)
HU (4) HUE025463T2 (el)
IL (2) IL178651A (el)
LT (1) LTC2422766I2 (el)
LU (2) LU92176I2 (el)
MX (2) MXPA06012493A (el)
NO (1) NO20065502L (el)
NZ (1) NZ550479A (el)
PL (2) PL1755555T3 (el)
PT (2) PT1755555E (el)
RU (1) RU2396943C2 (el)
SG (3) SG152292A1 (el)
SI (2) SI2422766T1 (el)
WO (1) WO2005105043A2 (el)
ZA (1) ZA200609350B (el)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) * 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0525254D0 (en) * 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
AU2008334547B2 (en) * 2007-12-13 2011-06-30 Novartis Ag Organic compounds
ES2396471T3 (es) * 2007-12-13 2013-02-21 Novartis Ag Procedimiento para reducir la tendencia de una sal de glicopirronio a agregarse durante el almacenamiento
CA2716936C (en) * 2008-02-26 2018-06-05 Elevation Pharmaceuticals, Inc. Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
MX2011011123A (es) * 2009-04-24 2011-11-04 Schering Corp Formulaciones de aglomerado utiles en inhaladores de polvo seco.
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
GB0921481D0 (en) * 2009-12-08 2010-01-20 Vectura Ltd Process and product
EP2552414A4 (en) * 2010-03-31 2014-05-14 Glenmark Pharmaceuticals Ltd PHARMACEUTICAL POWDER COMPOSITION FOR INHALATION
WO2011120779A1 (en) 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation
EP2560611B1 (en) * 2010-04-21 2018-01-03 Chiesi Farmaceutici S.p.A. "process for providing particles with reduced electrostatic charges"
EP3461474B1 (en) 2010-08-31 2020-11-11 GlaxoSmithKline Intellectual Property Development Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
AU2011298315B2 (en) 2010-08-31 2014-08-28 Glaxo Group Limited Dry powder inhalation drug products exhibiting moisture control properties and methods of administering the same
JO3510B1 (ar) * 2011-03-04 2020-07-05 Heptares Therapeutics Ltd استخدام جلايكوبيرولات لعلاج عدم انتظام دقات القلب
CA2869849A1 (en) 2012-04-13 2013-10-17 Glaxosmithkline Intellectual Property Development Limited Aggregate particles comprising nanoparticulate drug particles of umeclidinium bromide, vilanterol trifenatate and fluticasone furoate
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
JP6114841B2 (ja) 2013-02-28 2017-04-12 ダーミラ， インク．Ｄｅｒｍｉｒａ， Ｉｎｃ． グリコピロレート塩
SG11201507286QA (en) * 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
GB201305825D0 (en) * 2013-03-28 2013-05-15 Vectura Ltd New use
US9393202B2 (en) * 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
GB201402556D0 (en) 2014-02-13 2014-04-02 Crystec Ltd Improvements relating to inhalable particles
LT3191081T (lt) 2014-09-09 2020-07-10 Vectura Limited Vaisto forma, apimanti glikopiroliatą, būdas ir aparatūra
AU2015331915A1 (en) * 2014-10-16 2017-05-25 Teva Branded Pharmaceutical Products R&D, Inc. Dry powder formulation
US9925168B2 (en) 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
MX2018010781A (es) 2016-03-08 2018-11-09 Mereo Biopharma 1 Ltd Regimen de dosificacion para el tratamiento de exacerbaciones agudas de condiciones inflamatorias.
AU2016397047B2 (en) 2016-03-08 2022-04-07 Mereo Biopharma 1 Limited Dosage regimen for the treatment of acute exacerbations of chronic obstructive pulmonary disease
EP3490533B1 (en) 2016-07-29 2020-05-27 Inke, S.A. Particle size stabilization process
ES2968453T3 (es) 2016-09-19 2024-05-09 Mexichem Fluor Sa De Cv Composición farmacéutica que comprende glicopirrolato
EP3595631A1 (en) 2017-03-15 2020-01-22 Vectura Limited Method and formulation
WO2019060595A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
WO2019060604A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
CA3085545A1 (en) 2017-12-11 2019-06-20 Mereo Biopharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the treatment of acute exacerbations of chronic obstructive pulmonary disease
EP3845228A1 (en) 2017-12-11 2021-07-07 Mereo BioPharma 1 Limited Use of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-n-cyclopropyl-4-methylbenzamide in the prevention or reduction of acute exacerbations of chronic obstructive pulmonary disease
KR102696616B1 (ko) 2018-12-21 2024-08-20 한미약품 주식회사 흡입 제형용 건조 분말 및 이의 제조방법
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
CN118475343A (zh) 2021-12-21 2024-08-09 凯西制药公司 填充在具有改善的耐湿性的吸入器中的干粉制剂

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) * 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
US3709039A (en) * 1970-08-31 1973-01-09 Gen Time Corp Comfort humidity indicator
SE9302777D0 (sv) 1993-08-27 1993-08-27 Astra Ab Process for conditioning substances
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
US5612053A (en) * 1995-04-07 1997-03-18 Edward Mendell Co., Inc. Controlled release insufflation carrier for medicaments
GB9808470D0 (en) 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
CA2347856C (en) * 1998-11-13 2009-02-17 Jago Research Ag Dry powder for inhalation
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
KR100949539B1 (ko) 2000-06-27 2010-03-25 벡투라 리미티드 약학 조성물용 입자의 제조 방법
EP1337241B1 (en) * 2000-11-30 2008-01-02 Vectura Limited Method of preparing microparticles for use in pharmaceutical compositions for inhalation
EP1920763B2 (en) * 2000-11-30 2022-06-15 Vectura Limited Pharmaceutical compositions for inhalation
EP1372608B1 (de) * 2001-03-30 2007-10-10 Jagotec Ag Medizinische aerosolformulierungen
AU2003228907A1 (en) * 2002-05-07 2003-11-11 Nektar Therapeutics Capsules for dry powder inhalers and methods of making and using same
GB2405798A (en) * 2003-09-15 2005-03-16 Vectura Ltd Dry powder inhaler with primary and secondary piercing elements and a medicament pack for use with an inhalation device.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US7915303B2 (en) * 2005-03-24 2011-03-29 Sosei R&D Ltd. Glycopyrronium salts and their therapeutic use

Also Published As

Publication number Publication date
RU2006142322A (ru) 2008-06-20
MX341426B (es) 2016-08-18
EP2422767A3 (en) 2012-04-25
HUS1500072I1 (hu) 2016-02-29
PT1755555E (pt) 2012-08-17
EP1755555A2 (en) 2007-02-28
CA2563760C (en) 2013-07-02
BRPI0510500B8 (pt) 2021-05-25
AU2005237266A1 (en) 2005-11-10
PL2422766T3 (pl) 2015-11-30
EP2422766B1 (en) 2015-06-24
LU92392I2 (fr) 2015-11-02
HUE025463T2 (en) 2016-02-29
DK1755555T3 (da) 2012-08-20
PT2422766E (pt) 2015-10-12
HUS1500073I1 (hu) 2016-02-29
PL1755555T3 (pl) 2012-11-30
CN1964700A (zh) 2007-05-16
EP2422767A2 (en) 2012-02-29
EP1755555B1 (en) 2012-05-23
IL223545A (en) 2016-04-21
JP5124718B2 (ja) 2013-01-23
WO2005105043A3 (en) 2006-05-04
IL178651A0 (en) 2007-02-11
SI1755555T1 (sl) 2012-10-30
LU92176I9 (el) 2019-01-04
AU2011200543B2 (en) 2012-11-29
NO20065502L (no) 2007-01-24
HUS1300006I1 (hu) 2016-07-28
HK1167334A1 (en) 2012-11-30
KR20070033978A (ko) 2007-03-27
JP2007535522A (ja) 2007-12-06
ES2388289T3 (es) 2012-10-11
DK2422766T3 (da) 2015-08-31
CY2015059I1 (el) 2020-05-29
AU2011200543A8 (en) 2011-03-31
CA2563760A1 (en) 2005-11-10
WO2005105043A2 (en) 2005-11-10
CY1116655T1 (el) 2017-03-15
JP2012031209A (ja) 2012-02-16
CN102008453A (zh) 2011-04-13
SI2422766T1 (sl) 2015-10-30
LU92176I2 (fr) 2013-05-27
EP2422766A3 (en) 2012-04-25
US20080063719A1 (en) 2008-03-13
CY2014015I2 (el) 2015-12-09
JP5000483B2 (ja) 2012-08-15
IL223545A0 (en) 2013-02-03
CY2013012I2 (el) 2015-08-05
ZA200609350B (en) 2008-04-30
CY2015060I1 (el) 2020-05-29
EP2422766A2 (en) 2012-02-29
CN107252423A (zh) 2017-10-17
MXPA06012493A (es) 2007-01-29
NZ550479A (en) 2009-11-27
CY2013012I1 (el) 2015-08-05
AU2005237266B2 (en) 2010-11-11
SG186673A1 (en) 2013-01-30
AU2011200543A1 (en) 2011-03-03
CY1113069T1 (el) 2015-08-05
RU2396943C2 (ru) 2010-08-20
GB0409703D0 (en) 2004-06-02
IL178651A (en) 2012-12-31
ES2546982T3 (es) 2015-09-30
HK1095282A1 (en) 2007-05-04
KR101287919B1 (ko) 2013-07-18
SG152292A1 (en) 2009-05-29
LTC2422766I2 (lt) 2020-02-10
BRPI0510500B1 (pt) 2019-04-24
SG10201605001SA (en) 2016-08-30
BRPI0510500A (pt) 2007-10-30

Similar Documents

Publication Publication Date Title
CY2014015I1 (el) Μεθοδοι παρασκευης συνθεσεων ξηρης σκονης του γλυκοπυρρολικου
FR22C1008I2 (fr) Composition immunogène
DK3354263T3 (da) Tørpulverformuleringer
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
PL2335782T3 (pl) Zastosowanie kompozycji zawierającej HFCO-1233zd
BRPI0614464A2 (pt) preparação cosmética
CY2014030I1 (el) Θεραπευτικες συνθεσεις που περιλαμβανουν ingenol-3-angelate
ITMI20041252A1 (it) Composizioni perfluoroelastomeriche
AP2465A (en) Terpene-containing compositions and methods of making and using them
HK1115752A1 (en) Benzazole derivatives, compositions, and methods of use as
NO20055643D0 (no) Preparation of lodixanol
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
DE502006009254D1 (de) Herstellung von natriumdiformiat
IL184036A0 (en) Preparation of rosuvastatin
EP1845086A4 (en) N-SUBSTITUTED N-METHOXYCARBAMATES BY 2-SUBSTITUTED PHENYL GROUPS, THEIR SYNTHESIS AND THEIR APPLICATIONS
DE602005026361D1 (de) Make-up Zubereitung
DE602005012016D1 (de) Kosmetischer komprimierter Puder
DE602005016978D1 (de) Quecksilberfreisetzende Zusammensetzungen
ATE551899T1 (de) Feststoff-formulierung fungizider mischungen
ATE414501T1 (de) Antiperspirant-zusammensetzungen
DE502006004931D1 (de) Herstellung modifizierter lignocellulosematerialien
EP1954685A4 (en) FUROXANE COMPOUNDS, COMPOSITIONS AND METHODS OF USE
PL1816116T3 (pl) Kompozycje chemiczne i sposoby ich wytwarzania
DE602006020698D1 (de) Pulverlackzusammensetzungen
ATE515256T1 (de) Antiperspirans-zusammensetzungen